A Defining Year for Pharma and Biotech: How Competitive Intelligence Is Poised to Boldly Face The Challenges

Stepping into 2026, the life sciences sector seems to be approaching with a sort of ‘confidence with guardrails’. Particularly coming out of the biggest, tone-setting event of the year, the JP Morgan Healthcare Conference. Comparatively speaking, the energy seemed more subdued, but not in a discouraging way. Progress and innovation messaging prevailed, despite the reportedly ‘slow start’ to the dealmaking there in San Francisco.

A more deliberate pace, and in many ways, a more sustainable one. Hopeful, while not overlooking risks; eyes wide open to the challenges ahead, informed by the rear view, including ongoing and unpredictable policy shifts, looming patent cliffs, and efficiency gains in AI execution.

Volatility of US Policy

Still one of the ‘wild card’ forces, this will continue to shift global dynamics. The US administration’s healthcare reforms such as TrumpRx, MFN pricing, and the availability of CNPVs, are reshaping commercial models in real time. These are prompting companies to revisit new product commercial launch planning, market access strategies, and reconsidering approaches to communicating value.

Patent cliffs: Standing over the edge

Meanwhile, a new surge of patent cliffs looms, fast approaching across multiple therapeutic key areas, such as oncology, immunology, and cardio/metabolic, forcing many to ponder long-term strategies. Many of pharma’s largest players are navigating the same expiry windows, intensifying competition even more for late-stage assets. This may present as pushing more toward targeted acquisitions (many from OUS/China) and seeking lifecycle management plays, among other ways, for companies to reposition themselves optimally.

AI: The Execution Era

AI continues to accelerate and reshape competitive advantage, as evidenced by LS leaders making calculated bets based on a portfolio or program reprioritizations, favoring those with clearer development paths and strongest revenue-generating potential. Enter the execution era of AI. Described as both a catalyst and a leveler, the accelerant that is AI has now shifted from novelty to its practical and efficient execution. The competitive advantage no longer comes from simply having AI, but from how effectively teams integrate it into discovery, development, and decision-making.

Additionally, the regulatory environment is still navigating these new methodologies, still ideating ways in which to refine expectations around the implications of AI/algorithm-supported evidence. Many companies are learning that speed alone won’t make the cut. Other considerations that matter just as much are validation, transparency, and responsible and ethical deployment.

CI: A Unified Strategic View

For competitive intelligence teams, the convergence of scientific acceleration, uncertainty in global policy, and commercial pressure are constantly reshaping the role. Beyond monitoring competitors, the position now requires interpreting policy signals, understanding how AI is redistributing advantage, and anticipating how organizations will navigate the dual demands of innovation and affordability. The pace of change demands a more integrated, cross-functional approach, cohesively incorporating scientific insight, regulatory fluency, and commercial foresight.

The organizations that thrive will be those that balance caution with conviction, those that can read the signals without losing sight of the science. The landscape may be shifting, but the drive to innovate is still very much alive and kicking.

Let Fletcher Help You Apply Competitive Intelligence To Elevate Your Strategic Advantage.

To explore the benefits and opportunities for optimizing CI at your organization, contact Tina Witte, SVP of Life Sciences, today. Her team offers deep expertise across CI, MI, Strategic Decision Support, and Life Sciences, enabling organizations to anticipate change, refine decision‑making, and execute with confidence.